BRAVEHEART BIO INC
BRVENASDAQ🏆 #1924 by market capUS Equity
——
Quote unavailableTrack BRVE
Get earnings, price moves & breaking news on Telegram
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.96B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
No chart data available for BRVE.
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $17.86 – $32.00
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 90.0M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.25
- Dividend Yield
- —
BRAVEHEART BIO INC
BRVEFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout BRAVEHEART BIO INC
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.